What is the clinical evidence from this study?

Population: Angiotensin II-induced cardiac hypertrophy and hypertension (n=15). Intervention: EGFR antisense oligodeoxynucleotide (EGFR-AS) vs. Control / EGFR-sense. Primary outcome: Left ventricular/body weight (LV/BW) ratio (p=<0.01).

What does this research mean for the field?

Inhibition of the epidermal growth factor receptor using an antisense oligodeoxynucleotide attenuates angiotensin II-induced left ventricular hypertrophy and decreases blood pressure in hypertensive rats. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine whether inhibiting epidermal growth factor receptor (EGFR) with an antisense oligodeoxynucleotide attenuates Angiotensin II-induced left ventricular hypertrophy and hypertension.

August 18, 2026CirculationOpen Access

Angiotensin II–Induced Cardiac Hypertrophy and Hypertension Are Attenuated by Epidermal Growth Factor Receptor Antisense

Q: What are the key findings of this study?

EGFR antisense oligodeoxynucleotide normalized the left ventricular/body weight ratio (2.32 vs 2.75; P<0.01) and decreased blood pressure in Angiotensin II-infused hypertensive rats.

Q: What does this research mean for the field?

Inhibition of the epidermal growth factor receptor using an antisense oligodeoxynucleotide attenuates angiotensin II-induced left ventricular hypertrophy and decreases blood pressure in hypertensive rats. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To determine whether inhibiting epidermal growth factor receptor (EGFR) with an antisense oligodeoxynucleotide attenuates Angiotensin II-induced left ventricular hypertrophy and hypertension.

View Full Paper

Ask AI

Bookmark

Key result

EGFR antisense oligodeoxynucleotide reduces LV/BW ratio ~16% and lowers blood pressure in hypertensive rats.

P<0.01
n=15

Why the study?

To examine whether EGFR is involved in the development of left ventricular hypertrophy by inhibiting EGFR with a specific antisense oligodeoxynucleotide to attenuate Ang II-induced cardiovascular hypertrophic effects.

Does EGFR antisense oligodeoxynucleotide reduce Angiotensin II-induced cardiac hypertrophy and hypertension in rats?

Key Points

To determine whether inhibiting epidermal growth factor receptor (EGFR) with an antisense oligodeoxynucleotide attenuates Angiotensin II-induced left ventricular hypertrophy and hypertension.
Treated cultured vascular smooth muscle cells with EGFR antisense oligodeoxynucleotides (EGFR-AS, 2.5 µmol/L) to examine EGFR expression and ERK phosphorylation.
Infused rats with Angiotensin II (150 ng/h for 14 days) with or without continuous intravenous EGFR-AS (2 mg/kg) to evaluate blood pressure and left ventricular/body weight ratios.
Angiotensin II raised blood pressure to 184±6 mm Hg versus 122±3 mm Hg in controls (n=7; P<0.01), whereas EGFR-AS infusion significantly reduced blood pressure to 169±8 mm Hg (n=8; P<0.05).
Angiotensin II increased the left ventricular/body weight ratio to 2.75±0.08 compared to 2.33±0.07 in controls (P<0.01), which EGFR-AS normalized to 2.32±0.06 (P<0.01) while suppressing ERK phosphorylation.

Structured PICO

Does EGFR antisense oligodeoxynucleotide reduce Angiotensin II-induced cardiac hypertrophy and hypertension in rats?

Population

15 rats with Angiotensin II-infused hypertension and cultured vascular smooth muscle cells.

Intervention

Antisense oligodeoxynucleotide to EGFR (EGFR-AS) (2.5 micromol/L in vitro; 2 mg/kg continuous intravenous infusion in vivo)

Comparator

Control rats, Angiotensin II alone, and EGFR-sense

Outcome

Blood pressure (BP) and left ventricular/body weight (LV/BW) ratiosurrogate

Main Result

Absolute Event Rate: 2.32% vs 2.75%

p-value: p=<0.01

Inhibition of EGFR with antisense oligodeoxynucleotides attenuates Angiotensin II-induced hypertension and cardiac hypertrophy in a rat model, highlighting EGFR's role in Ang II signaling.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

EGFR antagonism attenuates Ang II-induced hypertrophy and hypertension in vivo; extends VSMC transactivation findings but leaves open clinical translation.

Cite This Study

Kagiyama et al. (2002) studied Angiotensin II-induced cardiac hypertrophy and hypertension (n=15). EGFR antisense oligodeoxynucleotide (EGFR-AS) vs. Control / EGFR-sense was evaluated on Left ventricular/body weight (LV/BW) ratio (p=<0.01). EGFR antisense oligodeoxynucleotide normalized the left ventricular/body weight ratio (2.32 vs 2.75; P<0.01) and decreased blood pressure in Angiotensin II-infused hypertensive rats.

synapsesocial.com/papers/6a8477f5f54da20a1578d660 https://doi.org/10.1161/01.cir.0000030181.63741.56

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

EGFR antagonism attenuates Ang II-induced hypertrophy and hypertension in vivo; extends VSMC transactivation findings but leaves open clinical translation.

Angiotensin II–Induced Cardiac Hypertrophy and Hypertension Are Attenuated by Epidermal Growth Factor Receptor Antisense

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Topics

Angiotensin II–Induced Cardiac Hypertrophy and Hypertension Are Attenuated by Epidermal Growth Factor Receptor Antisense

Key Points

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider